Canopy Growth (NASDAQ:CGC – Get Free Report) is anticipated to announce its Q2 2027 results before the market opens on Friday, November 6th. Analysts expect the company to post earnings of ($0.03) per share and revenue of $57.72 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2027 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 10:00 AM ET.
Canopy Growth (NASDAQ:CGC – Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.02) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.02. Canopy Growth had a negative net margin of 65.33% and a negative return on equity of 21.91%. The firm had revenue of $142.62 million for the quarter, compared to analyst estimates of $58.21 million. On average, analysts expect Canopy Growth to post ($0.10) EPS for the current fiscal year and ($0.07) EPS for the next fiscal year.
Canopy Growth Stock Performance
CGC opened at $0.75 on Thursday. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.04 and a quick ratio of 2.39. The firm has a fifty day moving average price of $0.85 and a 200 day moving average price of $0.99. Canopy Growth has a 1 year low of $0.64 and a 1 year high of $2.38. The stock has a market cap of $336.98 million, a P/E ratio of -1.67 and a beta of 0.87.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on CGC
About Canopy Growth
Canopy Growth Corporation is a cannabis company headquartered in Smiths Falls, Ontario, Canada. Founded in 2013, the company operates in the production, distribution and sale of cannabis and cannabis-related products for adult-use and medical markets.
Its product portfolio includes dried cannabis flower, pre-rolls, cannabis oils, softgels, vapes, beverages and edibles. Canopy Growth markets products under several brands, including Tweed, 7ACRES, Doja and Deep Space, with offerings designed for different consumer preferences and product segments.
Canopy Growth primarily serves the Canadian recreational and medical cannabis markets and has pursued international opportunities in selected medical-cannabis markets.
Read More
- Five stocks we like better than Canopy Growth
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.
